Please login to the form below
ribociclib
This page shows the latest ribociclib news and features for those working in and with pharma, biotech and healthcare.
Novartis sales top £13bn in Q3 as the company reviews its generic business Sandoz
ruxolitinib) up by 26%, spinal muscular atrophy gene therapy Zolgensma (onasemnogene abeparvovec-xioi) up by 28%, and cancer medicine Kisqali (ribociclib), which grew by 27% in sales revenue.
Latest news
-
Strong five-year survival data for Kisqali in breast cancer
Novartis has presented a final analysis of its phase 3 MONALEESA-2 trial showing a survival benefit of more than 12 months for its CDK4/6 inhibitor, Kisqali (ribociclib) in combination ... These remarkable ribociclib overall survival data are highly
-
Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO
Novartis also presented data from the phase 3 MONALEESA-3 trial analysing the efficacy and safety of Kisqali (ribociclib) in combination with fulvestrant in postmenopausal women with HR-positive/HER2-negative
-
Novartis' Kisqali shows long-term improvements in breast cancer patients
Exploratory analysis of OS results for Kisqali (ribociclib) plus fulvestrant as a first- or second-line treatment compared to fulvestrant alone in this patient population found that the Kisqali combination continued
-
Novartis weathers the COVID-19 storm in Q3, lifts outlook
In addition, sales of the company’s plaque psoriasis treatment Cosentyx (secukinumab) increased by 7%, with its HER2-negative breast cancer therapy Kisqali (ribociclib) also growing by 50%.
-
NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata
According to NICE, Ibrance now joins two other of its approved drugs – Novartis’ Kisqali (ribociclib) and Lilly’s Verzenio (abemaciclib) - as a treatment option for patients at this stage of the
More from news
Approximately 4 fully matching, plus 37 partially matching documents found.
Latest appointments
-
Ipsen boosts specialty care and R&D leadership teams
East. Most recently, Semerjian served as senior vice president and global launch head of ribociclib.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- Eli Lilly announces $450m investment in US manufacturing site
- Sanofi/Regeneron’s Dupixent recommended by CHMP for atopic dermatitis in children
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- EIT Health marks World Cancer Day with €6m pledge for new healthcare delivery models
- World Cancer Day: encouraging men to put their health first
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Strategic behaviour
- Tidepool’s automated insulin dosing app for type 1 diabetes gets FDA approval
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Alzheimer’s Society urges UK government to deliver on dementia plan
- GSK fires senior Chinese scientist over data fabrication
- NICE set to recommend seven biologics for severe rheumatoid arthritis
- World Cancer Day: encouraging men to put their health first
PMHub
3 Monkeys Zeno
3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
